Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: A review of human clinical trials

International Journal of Molecular Sciences

Volumn 17, Issue 6, 2016, Pages

  Sáez Lara, Maria Jose ^a   Robles Sanchez, Candido ^a   Ruiz Ojeda, Francisco Javier ^a,b   Plaza Diaz, Julio ^a,b   Gil, Angel ^a,b,c  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c Instituto de Salud Carlos III   (Spain)

Author keywords

Insulin resistance; Metabolic syndrome X; Non alcoholic fatty liver disease; Obesity; Probiotics; Randomized clinical trial; Synbiotics; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; CELL ADHESION MOLECULE; ENDOTOXIN; GAMMA INTERFERON; GLUCOSE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROBIOTIC AGENT; RETINOID RELATED ORPHAN RECEPTOR GAMMA; SHORT CHAIN FATTY ACID; SUPEROXIDE DISMUTASE; SYNBIOTIC AGENT; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANTIOXIDANT ACTIVITY; BODY MASS; CARBOHYDRATE METABOLISM; CLINICAL TRIAL (TOPIC); FAT MASS; GENE EXPRESSION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS PARACASEI; LACTOBACILLUS SALIVARIUS; METABOLIC STRESS; METABOLIC SYNDROME X; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STREPTOCOCCUS THERMOPHILUS; DIABETES MELLITUS, TYPE 2; META ANALYSIS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PROBIOTICS; SYNBIOTICS; TREATMENT OUTCOME;

EID: 84973618679     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17060928     Document Type: Review

References (67)

1. Backhed, F, Ley, R.E, Sonnenburg, J.L, Peterson, D.A, Gordon, J.I. Host bacterial mutualism in the human intestine. Science 2005, 307, 1915-1920. [CrossRef] [PubMed]
2. Hooper, L.V, Midtvedt, T, Gordon, J.I. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu. Rev. Nutr. 2002, 22, 283-307. [CrossRef] [PubMed]
3. Plaza-Díaz, J, Fernandez-Caballero, J.Á, Chueca, N, Garcia, F, Gómez-Llorente, C, Sáez-Lara, M.J, Fontana, L, Gil, A. Pyrosequencing analysis reveals changes in intestinal microbiota of healthy adults who received a daily dose of immunomodulatory probiotic strains. Nutrients 2015, 7, 3999-4015. [CrossRef] [PubMed]
4. McCoy, K.D, Köller, Y. New developments providing mechanistic insight into the impact of the microbiota on allergic disease. Clin. Immunol. 2015, 159, 170-176. [CrossRef] [PubMed]
5. Bass, R, Eneli, I. Severe childhood obesity: An under-recognised and growing health problem. Postgrad. Med. J. 2015, 91, 639-645. [CrossRef] [PubMed]
6. Lanthier, N, Leclercq, I.A. Adipose tissues as endocrine target organs. Best Pract. Res. Clin. Gastroenterol. 2014, 28, 545-558. [CrossRef] [PubMed]
7. Qin, J, Li, Y, Cai, Z, Li, S, Zhu, J, Zhang, F, Liang, S, Zhang, W, Guan, Y, Shen, D, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012, 490, 55-60. [CrossRef] [PubMed]
8. Forslund, K, Hildebrand, F, Nielsen, T, Falony, G, Le Chatelier, E, Sunagawa, S, Prifti, E, Vieira-Silva, S, Gudmundsdottir, V, Krogh Pedersen, H, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015, 7581, 262-266. [CrossRef] [PubMed]
9. Qin, J, Li, R, Raes, J, Arumugam, M, Burgdorf, K.S, Manichanh, C, Nielsen, T, Pons, N, Levenez, F, Yamada, T, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464, 59-65. [CrossRef] [PubMed]
10. Karlsson, F.H, Tremaroli, V, Nookaew, I, Bergström, G, Behre, C.J, Fagerberg, B, Nielsen, J, Bäckhed, F. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013, 498, 99-103. [CrossRef] [PubMed]
11. Turnbaugh, P.J, Hamady, M, Yatsunenko, T, Cantarel, B.L, Duncan, A, Ley, R.E, Sogin, M.L, Jones, W.J, Roe, B.A, Affourtit, J.P, et al. A core gut microbiome in obese and lean twins. Nature 2009, 457, 480-484. [CrossRef] [PubMed]
12. Sanchez, M, Darimont, C, Drapeau, V, Emady-Azar, S, Lepage, M, Rezzonico, E, Ngom-Bru, C, Berger, B, Philippe, L, Ammon-Zuffrey, C, et al. Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women. Br. J. Nutr. 2014, 111, 1507-1519. [CrossRef] [PubMed]
13. Hong, H.R, Ha, C.D, Kong, J.Y, Lee, S.H, Song, M.G, Kang, H.S. Roles of physical activity and cardiorespiratory fitness on sex difference in insulin resistance in late elementary years. J. Exerc. Nutr. Biochem. 2014, 18, 361-369. [CrossRef] [PubMed]
14. Juhan-Vague, I, Morange, P.E, Alessi, M.C. The insulin resistance syndrome: Implications for thrombosis and cardiovascular disease. Pathophysiol. Haemost. Thromb. 2002, 32, 269-273. [CrossRef] [PubMed]
15. Jun-Ling, H, Hui-Ling, L. Intestinal microbiota and type 2 diabetes: From mechanism insights to therapeutic perspective. World J. Gastroenterol. 2014, 20, 17737-17745.
16. Larsen, N, Vogensen, F.K, van den Berg, F.W.J, Nielsen, D.S, Andreasen, A.S, Pedersen, B.K, Al-Soud, W.A, Sørensen, S.J, Hansen, L.H, Jakobsen, M. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 2010, 5, e9085. [CrossRef] [PubMed]
17. Hulston, C.J, Churnside, A.A, Venables, M.C. Probiotic supplementation prevents high-fat, overfeeding-induced insulin resistance in human subjects. Br. J. Nutr. 2015, 113, 596-602. [CrossRef] [PubMed]
18. Ley, R.E, Bäckhed, F, Turnbaugh, P, Lozupone, C.A, Knight, R.D, Gordon, J.I. Obesity alters gut microbial ecology. Proc. Natl. Acad. Sci. USA 2005, 102, 11070-11075. [CrossRef] [PubMed]
19. World Health Organization and Food & Agriculture Organization. Guidelines for the Evaluation of Probiotics in Food; Report of a Joint FAO/WHOWorking Group on Drafting Guidelines for the Evaluation of Probiotics in Food; FAO/WHO: London, ON, Canada, 2002; Available online: http://ftp.fao.org/es/esn/food/wgreport2.pdf (accessed on 2 June 2016).
20. Plaza-Diaz, J, Gomez-Llorente, C, Abadia-Molina, F, Saez-Lara, M.J, Campaña-Martin, L, Muñoz-Quezada, S, Romero, F, Gil, A, Fontana, L. Effects of Lactobacillus paracasei CNCM I-4034, Bifidobacterium breve CNCM I-4035 and Lactobacillus rhamnosus CNCM I-4036 on hepatic steatosis in Zucker rats. PLoS ONE 2014, 9, e98401.
21. World Health Organization, Food and Agricultural Organization of the United Nations. Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria; FAO Nutrition Paper; FAO: Cordoba, Argentina, 2001; Volume 85, pp. 1-33.
22. Hill, C, Guarner, F, Reid, G, Gibson, G.R, Merenstein, D.J, Pot, B, Morelli, L, Canani, R.B, Flint, H.J, Salminen, S, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014, 11, 506-514. [CrossRef] [PubMed]
23. Kruis, W, Fric, P, Pokrotnieks, J, Lukás, M, Fixa, B, Kascák, M, Kamm, M.A, Weismueller, J, Beglinger, C, Stolte, M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004, 53, 1617-1623. [CrossRef] [PubMed]
24. Bermudez-Brito, M, Plaza-Díaz, J, Muñoz-Quezada, S, Gómez-Llorente, C, Gil, A. Probiotic mechanisms of action. Ann. Nutr. Metab. 2012, 61, 160-174. [CrossRef] [PubMed]
25. Fontana, L, Bermudez-Brito, M, Plaza-Diaz, J, Muñoz-Quezada, S, Gil, A. Sources, isolation, characterisation and evaluation of probiotics. Br. J. Nutr. 2013, 2, S35-S50. [CrossRef] [PubMed]
26. Pineiro, M, Asp, N.G, Reid, G, Macfarlane, S, Morelli, L, Brunser, O, Tuohy, K. FAO Technical meeting on prebiotics. J. Clin. Gastroenterol. 2008, 42, S156-S159. [CrossRef] [PubMed]
27. Upadhyay, N, Moudgal, V. Probiotics: A Review. J. Clin. Outcomes Manag. 2012, 19, 76-84.
28. Kim, S.W, Suda, W, Kim, S, Oshima, K, Fukuda, S, Ohno, H, Morita, H, Hattori, M. Robustness of gut microbiota of healthy adults in response to probiotic intervention revealed by high-throughput pyrosequencing. DNA Res. 2013, 20, 241-253. [CrossRef] [PubMed]
29. Ferrario, C, Taverniti, V, Milani, C, Fiore, W, Laureati, M, de Noni, I, Stuknyte, M, Chouaia, B, Riso, P, Guglielmetti, S. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. J. Nutr. 2014, 144, 1787-1796.
30. Yoo, J.Y, Kim, S.S. Probiotics and prebiotics: Present status and future perspectives on metabolic disorders. Nutrients 2016, 8, 173. [CrossRef] [PubMed]
31. Larsen, N, Vogensen, F.K, Gøbel, R.J, Michaelsen, K.F, Forssten, S.D, Lahtinen, S.J, Jakobsen, M. Effect of Lactobacillus salivarius Ls-33 on fecal microbiota in obese adolescents. Clin. Nutr. 2013, 32, 935-940. [CrossRef] [PubMed]
32. Gøbel, R.J, Larsen, N, Jakobsen, M, Mølgaard, C, Michaelsen, K.F. Probiotics to adolescents with obesity: Effects on Inflammation and metabolic syndrome. J. Pediatr. Gastroenterol. Nutr. 2012, 55, 673-678. [CrossRef] [PubMed]
33. Kadooka, Y, Sato, M, Imaizumi, K, Ogawa, A, Ikuyama, K, Akai, Y, Okano, M, Kagoshima, M, Tsuchida, T. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur. J. Clin. Nutr. 2010, 64, 636-643. [CrossRef] [PubMed]
34. Kadooka, Y, Sato, M, Ogawa, A, Miyoshi, M, Uenishi, H, Ogawa, H. Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial. Br. J. Nutr. 2013, 110, 1696-1703. [CrossRef] [PubMed]
35. Sharafedtinov, K.K, Plotnikova, O.A, Alexeeva, R.I, Sentsova, T.B, Songisepp, E, Stsepetova, J, Smidt, I, Mikelsaar, M. Hypocaloric diet supplemented with probiotic cheese improves body mass index and blood pressure indices of obese hypertensive patients—A randomized double-blind placebo-controlled pilot study. Nutr. J. 2013, 12, 138. [CrossRef] [PubMed]
36. Zarrati, M, Salehi, E, Nourijelyani, K, Mofid, V, Zadeh, M.J, Najafi, F, Ghaflati, Z, Bidad, K, Chamari, M, Karimi, M, et al. Effects of probiotic yogurt on fat distribution and gene expression of proinflammatory factors in peripheral blood mononuclear cells in overweight and obese people with or without weight-loss diet. J. Am. Coll. Nutr. 2014, 33, 417-425. [CrossRef] [PubMed]
37. Zarrati, M, Shidfar, F, Nourijelyani, K, Mofid, V, Hossein zadeh-Attar, M.J, Bidad, K, Najafi, F, Gheflati, Z, Chamari, M, Salehi, E. Lactobacillus acidophilus La5, Bifidobacterium BB12, and Lactobacillus casei DN001 modulate gene expression of subset specific transcription factors and cytokines in peripheral blood mononuclear cells of obese and overweight people. Biofactors 2013, 39, 633-643. [CrossRef] [PubMed]
38. Zarrati, M, Salehi, E, Mofid, V, Hossein Zadeh-Attar, M.J, Nourijelyani, K, Bidad, K, Shidfar, F. Relationship between probiotic consumption and IL-10 and IL-17 secreted by PBMCs in overweight and obese people. Iran. J. Allergy Asthma Immunol. 2013, 12, 404-406. [PubMed]
39. Agerholm-Larsen, L, Raben, A, Haulrik, N, Hansen, A.S, Manders, M, Astrup, A. Effect of 8 week intake of probiotic milk products on risk factors for cardiovascular diseases. Eur. J. Clin. Nutr. 2000, 54, 288-297. [CrossRef] [PubMed]
40. Rajkumar, H, Mahmood, N, Kumar, M, Varikuti, S.R, Challa, H.R, Myakala, S.P. Effect of probiotic (VSL#3) and W-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: A randomized, controlled trial. Mediat. Inflamm. 2014, 2014, 348959. [CrossRef]
41. Brahe, L.K, Le Chatelier, E, Prifti, E, Pons, N, Kennedy, S, Blædel, T, Håkansson, J, Dalsgaard, T.K, Hansen, T, Pedersen, O. Dietary modulation of the gut microbiota—A randomised controlled trial in obese postmenopausal women. Br. J. Nutr. 2015, 114, 406-417. [CrossRef] [PubMed]
42. Ivey, K.L, Hodgson, J.M, Kerr, D.A, Lewis, J.R, Thompson, P.L, Prince, R.L. The effects of probiotic bacteria on glycaemic control in overweight men and women: A randomised controlled trial. Eur. J. Clin. Nutr. 2014, 68, 447-452. [CrossRef] [PubMed]
43. Ivey, K.L, Hodgson, J.M, Kerr, D.A, Thompson, P.L, Stojceski, B, Prince, R.L. The effect of yoghurt and its probiotics on blood pressure and serum lipid profile; a randomised controlled trial. Nutr. Metab. Cardiovasc. Dis. 2015, 25, 46-51. [CrossRef] [PubMed]
44. Safavi, M, Farajian, S, Kelishadi, R, Mirlohi, M, Hashemipour, M. The effects of synbiotic supplementation on some cardio metabolic risk factors in overweight and obese children: A randomized triple-masked controlled trial. Int. J. Food Sci. Nutr. 2013, 64, 687-693. [CrossRef] [PubMed]
45. Ipar, N, Aydogdu, S.D, Yildirim, G.K, Inal, M, Gies, I, Vandenplas, Y, Dinleyici, E.C. Effects of synbiotic on anthropometry, lipid profile and oxidative stress in obese children. Benef. Microbes 2015, 6, 775-781. [CrossRef] [PubMed]
46. Leber, B, Tripolt, N.J, Blattl, D, Eder, M, Wascher, T.C, Pieber, T.R, Stauber, R, Sourij, H, Oettl, K, Stadlbauer, V. The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: An open label, randomized pilot study. Eur. J. Clin. Nutr. 2012, 66, 1110-1115. [CrossRef] [PubMed]
47. Tripolt, N.J, Leber, B, Blattl, D, Eder, M, Wonisch, W, Scharnagl, H, Stojakovic, T, Obermayer-Pietsch, B, Wascher, T.C, Pieber, T.R, et al. Effect of supplementation with Lactobacillus casei Shirota on insulin sensitivity, β-cell function, and markers of endothelial function and inflammation in subjects with metabolic syndrome—A pilot study. J. Dairy Sci. 2013, 96, 89-95. [CrossRef] [PubMed]
48. Barreto, F.M, Colado Simão, A.N, Morimoto, H.K, Batisti Lozovoy, M.A, Dichi, I, Helena da Silva Miglioranza, L. Beneficial effects of Lactobacillus plantarum on glycemia and homocysteine levels in postmenopausal women with metabolic syndrome. Nutrition 2014, 30, 939-942. [CrossRef] [PubMed]
49. Eslamparast, T, Zamani, F, Hekmatdoost, A, Sharafkhah, M, Eghtesad, S, Malekzadeh, R, Poustchi, H. Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome: A randomised, double-blind, placebo-controlled pilot study. Br. J. Nutr. 2014, 112, 438-445. [CrossRef] [PubMed]
50. Hariri, M, Salehi, R, Feizi, A, Mirlohi, M, Ghiasvand, R, Habibi, N. A randomized, double-blind, placebo-controlled, clinical trial on probiotic soy milk and soy milk: Effects on epigenetics and oxidative stress in patients with type II diabetes. Genes Nutr. 2015, 10, 52. [CrossRef] [PubMed]
51. Tonucci, L.B, Olbrich Dos Santos, K.M, Licursi de Oliveira, L, Rocha Ribeiro, S.M, Duarte Martino, H.S. Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Clin. Nutr. 2015. [CrossRef] [PubMed]
52. Mohamadshahi, M, Veissi, M, Haidari, F, Javid, A.Z, Mohammadi, F, Shirbeigi, E. Effects of probiotic yogurt consumption on lipid profile in type 2 diabetic patients: A randomized controlled clinical trial. J. Res. Med. Sci. 2014, 19, 531-536. [PubMed]
53. Ejtahed, H.S, Mohtadi-Nia, J, Homayouni-Rad, A, Niafar, M, Asghari-Jafarabadi, M, Mofid, V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition 2012, 28, 539-543. [CrossRef] [PubMed]
54. Ejtahed, H.S, Mohtadi-Nia, J, Homayouni-Rad, A, Niafar, M, Asghari-Jafarabadi, M, Mofid, V, Akbarian-Moghari, A. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J. Dairy Sci. 2011, 94, 3288-3294. [CrossRef] [PubMed]
55. Andreasen, A.S, Larsen, N, Pedersen-Skovsgaard, T, Berg, R.M, Møller, K, Svendsen, K.D, Jakobsen, M, Pedersen, B.K. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br. J. Nutr. 2010, 104, 1831-1838. [CrossRef] [PubMed]
56. Asemi, Z, Zohreh, Z, Shakeri, H, Sima-Sadat Sabihi, S.S, Esmaillzadeh, A. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Ann. Nutr. Metab. 2013, 63, 1-9. [CrossRef] [PubMed]
57. Tajadadi-Ebrahimi, M, Bahmani, F, Shakeri, H, Hadaegh, H, Hijijafari, M, Abedi, F, Asemi, Z. Effects of daily consumption of synbiotic bread on insulin metabolism and serum high-sensitivity C-reactive protein among diabetic patients: A double-blind, randomized, controlled clinical trial. Ann. Nutr. Metab. 2014, 65, 34-41. [CrossRef] [PubMed]
58. Shakeri, H, Hadaegh, H, Abedi, F, Tajabadi-Ebrahimi, M, Mazroii, N, Ghandi, Y, Asemi, Z. Consumption of synbiotic bread decreases triacylglycerol and VLDL levels while increasing HDL levels in serum from patients with type-2 diabetes. Lipids 2014, 49, 695-701. [CrossRef] [PubMed]
59. Moroti, C, Souza Magri, L.F, Rezende-Costa, M, Cavallini, D, Sivieri, K. Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis. 2012, 11, 29. [CrossRef] [PubMed]
60. Aller, R, De Luis, D.A, Izaola, O, Conde, R, Gonzalez Sagrado, M, Primo, D, de la Fuente, B, Gonzalez, J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur. Rev. Med. Pharmacol. Sci. 2011, 15, 1090-1095. [PubMed]
61. Vajro, P, Mandato, C, Licenziati, M.R, Franzese, A, Vitale, D.F, Lenta, S, Caropreso, M, Vallone, G, Meli, R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J. Gastroenterol. Nutr. 2011, 52, 740-743. [CrossRef] [PubMed]
62. Nabavi, S, Rafraf, M, Somi, M.H, Homayouni-Rad, A, Asghari-Jafarabadi, M. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J. Dairy Sci. 2014, 97, 7386-7393. [CrossRef] [PubMed]
63. Alisi, A, Bedogni, G, Baviera, G, Giorgio, V, Porro, E, Paris, C, Giammaria, P, Reali, L, Anania, F, Nobili, V. Randomised clinical trial: The beneficial effects of VLS≠3 in obese children with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2014, 39, 1276-1285. [CrossRef] [PubMed]
64. Sandoval, D.A, D’Alessio, D.A. Physiology of proglucagon petides: Role of glucagon and GLP-1 in health and disease. Physiol. Rev. 2015, 95, 513-548. [CrossRef] [PubMed]
65. Eslamparast, T, Poustchi, H, Zamani, F, Sharafkhah, M, Malekzadeh, R, Hetmatdoost, A. Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study. Am. J. Clin. Nutr. 2014, 99, 535-542. [CrossRef] [PubMed]
66. Lirussi, F, Mastropasqua, E, Orando, S, Orlando, R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst. Rev. 2007, 1, CD005165. [CrossRef] [PubMed]
67. Wong, V.W.; Won, G.L, Chim, A.M, Chu, W.C, Yeung, D.K, Li, K.C, Chan, L. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann. Hepatol. 2013, 12, 256-262. [PubMed]